The Traderszone Network

Is this meaningful? Or just another movement?

Earnings incoming: Here are the three questions management should answer on the earnings call.

Shares of Regeneron were down about 3 percent after the FDA approved Regeneron’s cholesterol-lowering drug Praluent.

In gleeful news for ardent Federal Reserve observers (and an embarrassment for officials), the central bank accidentally published internal staff forecasts for interest rates, unemployment and other key indicators.
read more

Gigamon beat the Street on every level, both in the second quarter and in third-quarter guidance. The stock was just running too hot at this point.

Clinton decried the effects of some activist investors, calling out firms that have seen involvement from Carl Icahn and others.

A bearish engulfing chart pattern is warning that the financial sector’s uptrend, that took it a multiyear high earlier this week, may have just ended.
read more